Methods of treating hidradenitis suppurativa

Patent metadata

Field	Value
Publication number	US-11844790-B2
Application number	US-202117512335-A
Country	US
Kind code	B2
Filing date	Oct 27, 2021
Priority date	Oct 28, 2020
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

First claim

What is claimed is:

1. A method of treating Hidradenitis Suppurativa (HS) in a subject in need thereof, said method comprising administering to said subject a compound of Formula I,

or a pharmaceutically acceptable salt thereof, wherein said subject receives about 30 mg of the compound twice daily, wherein said subject has a Hurley score of Stage III, and wherein
each R 1 is independently selected from the group consisting of CH 3 , CF 3 , CH 2 CH 3 , Cl, 1-pyrrolidine, —O—CH(CH 3 ) 2 , and CH 2 OH; and
each R 2 is independently selected from the group consisting of CH 3 and F.

2. The method of claim 1 , wherein the compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is Avacopan, having the formula

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the subject receives treatment for 12 weeks.

6. The method of claim 1 , wherein the subject receives treatment for 26 weeks.

7. The method of claim 1 , wherein the subject receives treatment for 52 weeks.

8. The method of claim 1 , wherein the subject receives chronic treatment.

Assignees

• Chemocentryx Inc

Inventors

• Li Shijie
• Singh Rajinder
• Schall Thomas J
• Staehr Peter

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K31/451 Primary

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title

• A61P17/00 Primary

  Drugs for dermatological disorders · CPC title

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title